Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG

Status: Recruiting
DFCI Protocol ID: 17-532

The purpose of this study is to investigate the activity of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive relapsed or refractory high grade glioma.

Conducting Institutions:

Children's Hospital Boston, Dana-Farber Cancer Institute

Overall PI:

Mark Kieran, MD, Dana-Farber Cancer Institute

Site-responsible Investigators:


Dana-Farber Cancer Institute: Childrens Hospital Pediatric Clinical Translation Investigation Program CTIP,

Eligibility Criteria

Inclusion Criteria:

  -  Diagnosis of High Grade glioma

  -  Relapsed, progressed or failed to respond to frontline therapy.

  -  Able to swallow capsules

Exclusion Criteria:

  -  Previous treatment with dabrafenib, trametinib, other RAF inhibitor, other MEK or ERK

  -  Cancer treatment within the past 3 weeks

  -  Stem cell transplant within the past 3 months

  -  History of heart disease

  -  Pregnant or lactating females

Know Your Options

Not sure which clinical trials might be right for your child? Email our clinical trials team at
We can help you navigate your options.

Get Clinical Trial Updates


Stay informed about Dana-Farber/Boston Children's research efforts, including information on new and current clinical trials. Sign up to receive our email newsletter Advances in Pediatric Hematology/Oncology.